Skip to main content

Table 2 Immunologic marker levels in comparative groups: surviving vs. non-surviving, ARDS vs. non-ARDS

From: Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis

 

Non-Surviving Patients

[total n = 16] (CI)

Surviving Patients

[total n = 14] (CI)

Pvalue

Non-ARDS Patients

[total n = 13] (CI)

ARDS Patients

[total n = 17] (CI)

Pvalue

HMGB-1 (ng/mL)a

11.76 [13] (-5.65-60)

6.78 [12] (4.5-17.66)

.44

10.11 [11] (4.64-18.97)

11.11 [14] (-4.83-55.51)

.64

RAGE (MFI)a

88.88 [15] (55.9-150.8)

116.7 [14] (51.9-456.2)

.21

98.01 [12] (6.68-492.31)

90.63 [17] (75.55-173.27)

.94

sRAGE (pg/mL)a

3236 [15] (2312-3673)

1037 [13] (912.8-2769)

.058

1829.75 [13] (1079-2629)

3296 [15] (2168-3793)

.058

  1. HMGB-1, high mobility group box -1, RAGE, receptor for advanced glycation end products; sRAGE, soluble RAGE; MFI, mean fluorescence intensity
  2. [n] Expresses the numeral of results analyzed, from the total number
  3. aData is expressed as median (CI)